Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. increased by $2,500,000 the maximum aggregate amount of its common stock that may be issued under its at-the-market sales agreement with Rodman & Renshaw LLC, through a new prospectus supplement. The company previously sold about $6,234,000 of common stock under earlier supplements that covered up to $6,406,000 of shares. The 8-K also files the related legal opinion from Duane Morris LLP as an exhibit.
Soligenix, Inc. amends its prior prospectus supplements to reset the available At-The-Market capacity under its Sales Agreement with Rodman & Renshaw LLC to $2,500,000. This Prospectus Supplement replaces unsold amounts under the Prior Prospectus and permits the company to offer and sell common stock from time to time under the Sales Agreement.
The Prior Prospectus had authorized up to an aggregate offering price of $6,406,000, of which shares with an aggregate price of approximately $6,234,000 were sold. The company reports a public float of $30,702,784 based on 21,621,679 shares held by non-affiliates and a per-share price of $1.42 as of April 27, 2026. Pursuant to Form S-3 General Instruction I.B.6, Soligenix discloses it has sold securities with an aggregate market value of $7,700,914 in the prior 12-calendar-month period.
SOLIGENIX, INC. ownership disclosure: MJL Manager LLC reports beneficial ownership of 893,588 shares (5.2%), Michael Liu reports 983,588 shares (5.7%), and Capuchin Capital Fund LP reports 539,737 shares (3.1%). The filing states Michael Liu has sole voting and dispositive power over 90,000 shares and shared voting/dispositive power over the larger pooled positions. The filing notes MJL Manager LLC is the general partner of Capuchin Capital Fund LP and manages discretionary accounts with authority to direct voting and disposition of shares.
Soligenix, Inc. is ending development of its HyBryte™ therapy and has received a Nasdaq warning about its share price. The board decided on June 11, 2026 to terminate the HyBryte™ program after an interim analysis of the Phase 3 FLASH2 trial recommended stopping for futility. The company will wind down the study and related work and expects about $70,000 in close‑out charges. Soligenix also received notice on June 10, 2026 that its stock has traded below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a 180‑day grace period, until December 7, 2026, to regain compliance. If needed and other listing conditions are met, Soligenix may seek an additional 180‑day period, potentially via a reverse stock split. In connection with ending HyBryte™, Consulting Chief Medical Officer Dr. Richard Straube’s role will wind down, with responsibilities shifting to Medical Director Dr. Christopher Pullion. The company plans to evaluate strategic options, including mergers and acquisitions, and focus on other pipeline assets such as dusquetide (SGX945) for Behçet’s Disease.
Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,956,000.
The company previously sold approximately $3,445,000 of common stock under this agreement pursuant to an earlier prospectus supplement. A legal opinion from Duane Morris LLP covering the additional $2,956,000 of common stock is included as an exhibit, along with the related consent and an Inline XBRL cover page data file.
Soligenix, Inc. amends its prospectus supplement to set an at-the-market offering capacity of $2,956,000 of common stock under the Sales Agreement with Rodman & Renshaw LLC. The company reports a public float of $24,511,625 based on 17,261,708 shares held by non-affiliates at $1.42 per share as of April 27, 2026. The supplement notes prior sales of $5,214,498 under the Form S-3 instruction during the preceding 12-month period and lists a last reported sale price of $0.87 on May 27, 2026.
Soligenix, Inc. files a Prospectus Supplement No. 1 dated May 8, 2025, registering 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and updates the Final Prospectus. As of May 1, 2026, shares outstanding were 14,824,174. The Form 10-Q shows cash of $6,029,430, a net loss of $(2,824,965) for the quarter, and management discloses that substantial doubt exists about the Company’s ability to continue as a going concern; management expects cash runway into 2027 but notes additional financing is required. The supplement also references an At-Market Issuance Sales Agreement providing up to $3.5M aggregate potential gross proceeds, with approximately $0.8M capacity remaining as of May 1, 2026.
Soligenix, Inc. files a Prospectus Supplement and Form 10-Q and registers 4,253 shares of common stock underlying previously issued common warrants.
The company reported $6,029,430 in cash and cash equivalents and a net loss of $2,824,965 for the three months ended March 31, 2026. As of May 1, 2026, 14,824,174 shares were outstanding. Management states cash runway to support operations into 2027 but also notes substantial doubt about the ability to continue as a going concern and plans to seek additional financing, including sales under an ATM facility with remaining capacity of approximately $0.8 million. The Data Monitoring Committee recommended halting the FLASH2 Phase 3 trial for futility and the company is analyzing the data to determine causes.
Soligenix, Inc. supplements its March 31, 2026 prospectus to register for resale up to 1,054,688 shares of common stock issuable upon exercise of previously issued warrants by the selling stockholders. The supplement includes the Company’s Form 10-Q for the quarter ended March 31, 2026.
Key reported figures: cash and cash equivalents of $6,029,430, a net loss of $(2,824,965) for Q1 2026, and 14,824,174 shares outstanding as of May 1, 2026. Management states cash runway to support operations into 2027 but also discloses that these factors raise substantial doubt about the Company’s ability to continue as a going concern. The prospectus supplement is a resale registration for selling holders; proceeds treatment is described in the Final Prospectus.
Operational update: the Data Monitoring Committee recommended halting the FLASH2 Phase 3 HyBryte™ trial for futility; the Company is analyzing the data.
Soligenix, Inc. filed a Prospectus Supplement registering 5,330,560 shares of common stock underlying previously issued common warrants.
The supplement, dated May 8, 2026, supplements the prospectus dated March 31, 2026 and includes the Form 10-Q for the quarter ended March 31, 2026. The filing also discloses cash and cash equivalents of $6,029,430, a net loss of $2,824,965 for the quarter, and management's statement that current resources and plans provide cash runway into 2027. As of May 1, 2026, 14,824,174 shares of common stock were outstanding.